ClinicalTrials.gg
RecruitingNCT06511063Updated Mar 13, 2026

Antiviral Clinical Trial for Long Covid-19

A Phase 2 interventional study of tenofovir disoproxil/emtricitabine and Selzentry in Long Covid, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai — 6 open to participants now, 7 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Icahn School of Medicine at Mount Sinai.

Planned enrollment
3rd of 10
90 · median 45
Started
2024
with 3 others
Phase 2
2 of 10
2 open now
Registered
3rd of 10
by date

Among the 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2024, is one of 2 in phase 2, and was the 3rd registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

6 of the 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid.

Participants will be randomly allocated to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine, TDF/FTC, Group 1) or Selzentry (Group 2), or a placebo (pill) (Group 3), taken daily for 90 days.

03

Conditions studied

  • Long Covid

Keywords

  • Long Covid
  • Antiviral
  • Truvada
  • Selzentry
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Any gender, aged 18+
  • Diagnosed with:

    • Long Covid
    • Documented clinical history of confirmed or suspected acute SARS-CoV-2 infection a minimum of 6 months prior to contact with the study team
    • Formal diagnosis of Long Covid from a physician and a history of 6 months of Long COVID symptoms
  • At least a six-month history of one of the following symptoms following SARS-CoV-2 infection:

    • headache, memory loss, insomnia, mood disturbance, chest pain, palpitations, shortness of breath, cough, muscle pains, joint pains, or GI upset] AND at least moderate fatigue (measured by Fatigue Severity Score) AND at least moderate post-exertional malaise (PEM) (measured by DePaul PEM screener)
  • Participants who are willing and able to comply with all data collection, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected before randomization as part of the baseline survey).

Exclusion criteria

Exclusion Criteria:

  • Pre-existing conditions including, but not limited to:

    • conditions such as Chronic EBV, Multiple Sclerosis, Hashimoto's Disease, etc. which would impact the immunological profiling analysis.
    • A pre-2020 diagnosis of another Post-Acute Infectious Syndrome such as Chronic Lyme disease, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, etc.
    • Documented history of vaccine injury
    • Or any other chronic condition that has the potential to impact on immunological profiling, at the discretion of the research physician
  • + status
  • Current use of either Truvada or Selzentry
  • Taking a medication, within 6 weeks, with known interactions with Truvada or Selzentry including but not limited to: Acyclovir, valacyclovir, adefovir, cabozantinib, carbamazepine, cidofovir, cladribine, cobicistat, diclofenac, multiple NSAIDs or chronic high dose NSAIDs, fosphenytoin or phenytoin, ganciclovir, valganciclovir, oxcarbazepine, phenobarbital, primidone, rifabutin, rifampin, rifapentine, sofosbuvir, tipranavir, or other drugs that significantly affect renal function
  • Current treatment with drugs known to affect EBV replication, including but not limited to: Acyclovir, valacyclovir, ganciclovir, valganciclovir, famciclovir, teriflunomide, interferon
  • Known allergic reactions to components of Truvada or Selzentry
  • Febrile illness within the last 3 months of planned baseline evaluation
  • Treatment with another drug or other investigational intervention within 6 months of planned baseline evaluation
  • individuals (transplant on antiviral prophylaxis and/or patients taking immunosuppressive medications such as , etc.)
  • Known medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic or active or C infection, primary biliary cirrhosis, Class B or C, or acute liver failure
  • Receiving dialysis or have known renal impairment
  • Any comorbidity requiring hospitalization and/or surgery within 7 days prior to study entry, or that is considered life threatening within days prior to study entry, as determined by the study team
  • Other medical or psychiatric conditions, in the treating investigator's judgment, that makes the participant inappropriate for the study
  • Unknown HIV status (subjects must have completed HIV antigen/antibody and viral load testing completed at the screening visit)
  • Active or latent hepatitis B (subjects must have completed HBV serologies - HbsAg, anti-HBs, and anti-HBc - testing completed at the screening visit)
  • Current symptoms of severe, progressive, or uncontrolled renal, hematologic, gastrointestinal, pulmonary, cardiac, or neurologic disease, or other medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study
  • (CrCl) \<75mL/min, as calculated by the Cockcroft-Gault equation
  • Any history of bone fractures not explained by trauma
  • Confirmed Grade 2 or greater hypophosphatemia
  • Any Grade 2 or greater toxicity on screening tests and assessments
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Truvada (Tenofovir Disoproxil Fumarate, TDF/FTC, tenofovir disoproxil/emtricitabine)

    Participants will take 300mg tenofovir disoproxil fumarate/200 mg emtricitabine, once per day, and one placebo capsule per day, oral capsule for 90 days.

    Drug: tenofovir disoproxil/emtricitabine · Drug: Placebo

  • Experimental
    Selzentry

    Participants will take 300 mg of Selzentry, twice a day, oral capsule for 90 days.

    Drug: Selzentry

  • Placebo comparator
    Placebo

    Participants will take a placebo, twice per day, oral capsule for 90 days.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale

    The EQ-5D-5L is a standardized measure of health status that consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each with 5 levels of severity, and a visual analogue scale (VAS) where individuals rate their overall health from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: at Screening, Day 60, Day 90, and Day 180

Secondary outcomes

  1. The EuroQol Five-Dimensional Health Questionnaire (EQ-5D-5L)

    The EQ-5D-5L is a validated, standardized, generic instrument that is a preference-based health- related quality of life questionnaire. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Full scale from 5 to 25, with higher score indicating poorer health outcomes.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  2. Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29)

    The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. The values of all item responses are averaged to generate subscores for each dimension. From these subscores, a global physical health score and a global mental health score are generated. The scores are translated into T-scores according to a reference population with a mean of 50 and a standard deviation of 10.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  3. General Symptom Questionnaire (GSQ-30)

    The General Symptom Questionnaire-30 (GSQ-30) is a valid and reliable instrument to assess symptom burden among patients with acute and post-treatment. The GSQ-30 total score ranges from 0 to 120, with higher scores indicating a greater symptom burden.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  4. Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a series of questions assessing presence and severity of depression symptoms. It evaluates each of the DSM-IV depression criteria and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. Full scale from 0-27, with higher score indicating more severe symptoms.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  5. Generalized Anxiety Disorder (GAD-7)

    The GAD-7 is a 7-item scale developed and validated to identify generalized anxiety disorder and its severity. It assesses the frequency of 7 anxiety symptoms and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). Total scores of 5, 10, and 15 correspond to mild, moderate, and severe generalized anxiety disorder, respectively. Full scale from 0-21, with higher score indicating more symptoms.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  6. Neuro-QoL™ v2.0 Cognitive Function-Short Form

    The Neuro-QoL Cognitive Function v2.0 short form assesses perceived difficulties in cognitive abilities, including memory, attention, decision making, planning, organizing, calculating, remembering, and learning. The short form consists of 8 questions assessed on a 5-point Likert scale, resulting in a raw score range of 8 to 40. A raw score is then converted to a T-score using conversion tables. Scores 0.5 - 1.0 SD worse than the mean (T-score 40-45) = mild symptoms/impairment. Scores 1.0 - 2.0 SD worse than the mean (T-score 30-40) = moderate symptoms/impairment. Scores 2.0 SD or more worse than the mean (T-score below 30) = severe symptoms/impairment.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  7. Single-item Sleep Quality Scale (SQS)

    The SQS is a visual analog scale that instructs respondents to rate their overall quality of sleep over a 7-day recall period from 0 to 10. Scores of 0, 1, 4, 7, and 10 correspond to terrible, poor, fair, good, and excellent, respectively. Higher scores indicate better sleep quality.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  8. Fatigue Severity Scale (FSS)

    The Fatigue Severity Scale (FSS) uses a 7-point scale (1-7) to assess fatigue, with higher scores indicating greater severity, and a total score ranging from 9 to 63. Higher scores indicate more severe fatigue.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  9. Fatigue Visual Analogue Scale (F-VAS)

    The F-VAS consists of 18 items related to fatigue and energy in a visual analogue scale from 0 to 100. A higher score indicates more fatigue.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  10. DePaul Post-Exertional Malaise Questionnaire (DSQ)

    The DSQ is designed to evaluate 54 classic ME/CFS symptoms, including fatigue, post-exertional malaise, sleep, pain, neurological/cognitive impairments, and autonomic, neuroendocrine, and immune symptoms. Each symptom's frequency and intensity are rated on a 5-point scale (0-4). Frequency and severity scores are multiplied by 25, added together, and then divided by 2 to create a composite frequency/severity score for each symptom. These scores range from 0 to 100, with higher scores indicating a greater symptom burden.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  11. Composite Autonomic Symptom Score 31(COMPASS-31)

    The COMPASS-31 is a 31-question self-assessment instrument of autonomic symptoms and function that is up-to-date, broadly applicable, easy to administer in a short amount of time, and based on a scientific approach. The total score ranges from 0 to 100, with higher scores indicating greater autonomic dysfunction.

    Time frame: at Screening, Day 60, Day 90, and Day 180

  12. Pain Visual Analogue Scale (P-VAS)

    Using a visual analogue scale, patients mark a point on a line representing a continuum from "no pain" to "worst pain," with scores ranging from 0 to 100, where higher scores indicate greater pain.

    Time frame: at Screening, Day 60, Day 90, and Day 180

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Nov 2026, 25 months after the start.

Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 25 months is above that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Jul 19, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06511063
Collaborators
Yale University, PolyBio Research Foundation
Responsible party
David Putrino (Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jul 19, 2024
Start date
Oct 1, 2024
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 13, 2026

Study contacts

David Putrino, PhD, PT
Contact
CoreResearch@mountsinai.org
212-241-8454
Mackenzie Doerstling, MPH
Contact
CoreResearch@mountsinai.org
212-241-8454
David Putrino, PhD, PT
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tenofovir · Emtricitabine · Maraviroc

Start the discussion